Amydis Diagnostics, Inc. receives a Phase 1 SBIR grant award from the National Institute on Aging of the National Institutes of Health (NIH). Amydis is a privately-held pharmaceutical company developing proprietary chemistry and innovative approaches for the detection of amyloid-related diseases. The grant award for more than $530,000 will fund research and development efforts for novel ophthalmic diagnostic probes for Cerebral Amyloid Angiopathy (CAA).
Detecting amyloid proteins in the retina
“We are honored to have been selected for this highly competitive grant from NIH, our third award in the past three years. It will allow us to accelerate the development of our innovative chemistry and expand into another disease that involves the presence of amyloid proteins,” stated Stella Sarraf, Ph.D., Chief Executive Officer and Founder of Amydis Diagnostics, Inc. “We believe that the eye represents a window to the brain and can be used as a proxy for diagnosing certain neurological diseases. To our knowledge, we are the first company to explore the possibility of detecting amyloid proteins in the retina associated with CAA.”
Source: GlobeNewswire | 9 October 2017